summary:
Jordan Xu, Managing Director of DROFEN Machinery, has published his fourth technical article in Pharmaceutical Technology (PharmTech). Published on October 26, 2026, "From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly" examines how equipment requirements can be translated into observable, testable interface behavior and retained acceptance evidence.
The article addresses a practical question for pharmaceutical manufacturers, device producers and CDMOs: after a station detects an abnormal condition, how does the team demonstrate that the correct assembly receives the required action and that its record remains meaningful? This acceptance perspective complements Jordan's earlier work on insulin pen pre-assembly machines, empty-mechanism integration and cartridge-based final assembly.
From an inspection feature to a verified decision chain
An automatic-rejection function is not fully described by a sensor specification or a reject command. The acceptance criteria must connect the inspection result to the correct physical assembly, specify the required disposition and define how removal is confirmed.
The new contribution examines reusable carriers, missing or delayed results, controlled restarts and communication retries. It also explains why a record that has arrived at its destination may still be retransmitted if its acknowledgment is lost, and why this situation belongs in interface testing.
These scenarios are proposed engineering test designs, not reported customer incidents or production performance results. Their purpose is to show how a requirement can lead to a deliberate challenge, an observable response and evidence that can be investigated later.
Why insulin pen pre-assembly needs its own acceptance strategy
An insulin pen pre-assembly machine assembles injection-molded components and associated mechanical parts into an empty pen mechanism. Component presence alone does not establish correct orientation, seating depth or engagement. These are different verification tasks, with different sensors and acceptance criteria.
Jordan's PharmTech article on multicomponent pen injector pre-assembly explains this process-level challenge. Vision can verify specified orientation features, while linear variable differential transformer (LVDT) measurements can assess seating depth or height. Relevant functional checks remain necessary; an image or height reading is not automatically a substitute for them.
The newer requirements-to-evidence method adds a complementary line-level question: if one pre-assembly station produces an unacceptable or missing result, how should subsequent stations respond, and how will the team demonstrate that the correct mechanism was segregated? The application must be developed for the actual equipment sequence, not copied unchanged from a cartridge press-fit example.
For engineers selecting injector sub-assembly equipment, this links component variation and station verification with disposition, controlled restart and the agreed output specification. The downstream final assembly process then receives an empty mechanism with defined acceptance requirements, rather than an undefined "assembled pen."
Building on process engineering, not replacing it
The new publication extends Jordan's earlier discussions at the point where process measurements become line-level decisions. His PharmTech analysis of cartridge press-fit in final assembly examines force–displacement monitoring and assembly verification. The latest article adds a different question: does the resulting decision stay associated with the right assembly through transport, rejection and interruption?
Upstream, his article on dimensional variability in pen injector pre-assembly considers component orientation and mechanical relationships within the empty mechanism. Pre-assembly builds that mechanism from its components. Cartridge-based final assembly subsequently integrates an already-filled cartridge with the suitable pre-assembled mechanism; it is not the sterile filling operation.
Operating conditions also matter. The earlier PharmTech discussion of fill-finish and automated pen-assembly capacity bottlenecks provides the throughput context. Interface tests need to reflect the intended sequence and operating range, rather than only isolated station demonstrations.
Linking system strategy, URS planning and acceptance evidence
Jordan's ONdrugDelivery Expert View on fragmented procurement and integrated assembly explores why individually capable systems still need agreed interface responsibilities. The fourth PharmTech contribution moves from that system-level discussion to the method for testing those responsibilities.
DROFEN's existing guide, "Injection Pen Assembly URS: Interfaces to Define Before Design Freeze", provides a complementary planning perspective: define incoming device and container specifications, product-status handling, records, change control and test ownership before the equipment baseline is frozen. The new PT article asks how those requirements will be challenged and supported by evidence.
Factory acceptance testing (FAT) and site acceptance testing (SAT) have different dependencies. A factory test can establish behavior on the supplied configuration, with its simulations clearly identified. Actual site networks, receiving-system mappings and operating procedures may require additional verification. Equipment acceptance does not replace product verification, process validation or the manufacturer's quality decisions.
Applying the engineering discussion to a project
The DROFEN pre-assembly engineering guide develops the empty-mechanism equipment perspective. The final assembly engineering guide addresses the subsequent container-integration route. For the overall manufacturing structure, readers can refer to The Complete Technical Guide to Injection Pen Assembly Lines.
DROFEN MACHINERY EQUIPMENT CO., LTD. provides injection pen pre-assembly equipment and final assembly equipment. Depending on the agreed project scope, DROFEN can also coordinate injection pen supply, device-platform support, matching final assembly equipment and regulatory and qualification documentation support. A customer purchasing pre-assembled devices does not automatically need its own pre-assembly machine.
A useful initial discussion starts with the selected device and container, incoming material state, output requirements and the interfaces still open before design freeze. Contact DROFEN at xuz@drofen-pharma.com to discuss a non-confidential project outline. Detailed technical information can follow under agreed disclosure arrangements.
About Jordan Xu
Jordan Xu is Managing Director of DROFEN Machinery. His published technical writing covers injection pen assembly, manufacturing integration and acceptance evidence. His four PharmTech contributions are listed on the publisher's Jordan Xu author page. His ONdrugDelivery work appears on its author profile, and his publication record is maintained on ORCID.